source
- Zanubrutinib shows longer overall survival than ibrutinib in real-world relapsed/refractory mantle cell lymphomaA retrospective real‑world analysis examined outcomes of covalent BTK inhibitors in patients with relapsed or refractory mantle cell lymphoma who received treatment in the second or third line. Th…
- Medicare falls short on projected Alzheimer’s drug costs as fewer seniors use LeqembiBob Herman reports that Medicare's earlier estimate that the new Alzheimer's therapy Leqembi would cost the program $3.5 billion in 2025 has proved far too high. The agency's actuaries based the fo…STAT · 4mo agoRegulatoryNegative